Edition:
United Kingdom

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

6.87CAD
25 Apr 2018
Change (% chg)

$-0.07 (-1.01%)
Prev Close
$6.94
Open
$7.02
Day's High
$7.02
Day's Low
$6.74
Volume
23,005
Avg. Vol
46,866
52-wk High
$11.07
52-wk Low
$5.68

Chart for

About

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead... (more)

Overall

Beta: 3.31
Market Cap(Mil.): $587.72
Shares Outstanding(Mil.): 84.05
Dividend: --
Yield (%): --

Financials

  AUP.TO Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -1.47 -- --
ROI: -61.35 -0.73 12.97
ROE: -70.20 -2.77 14.84

BRIEF-Aurinia Pharmaceuticals Reports Qtrly Loss Per Share ‍of $0.04​

* AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

15 Mar 2018

BRIEF-Aurinia Pharmaceuticals Files For Mixed Shelf Of Up To $250 Mln

* AURINIA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING Source text: [http://bit.ly/2CTvkK1] Further company coverage:

04 Jan 2018

BRIEF-Aurinia Pharmaceuticals Added To The Nasdaq Biotech Index

* AURINIA PHARMACEUTICALS ADDED TO THE NASDAQ BIOTECH INDEX Source text for Eikon: Further company coverage:

11 Dec 2017

BRIEF-Aurinia reports Q3 loss per share $0.16

* Aurinia reports third quarter 2017 financial results and provides operational highlights

14 Nov 2017

Earnings vs. Estimates